Anaplastic lymphoma kinase (ALK) chromosomal rearrangement in NSCLC was originally described in 2007 (2) and affects approximately 3%–5% of patients with NSCLC (3–5). This evidence concerns the gene ALK and non-small cell lung carcinoma.